Abata Therapeutics Reports the US FDA’s IND Clearance for P-I Trial of ABA-101 for Progressive Multiple Sclerosis


The US FDA has cleared the IND application to commence FIH P-I trial of ABA-101 for treating progressive multiple sclerosis (MS), anticipated by the YE’24
The in vivo non-clinical study depicted ABA-101’s tolerability and its ability of producing anti-inflammatory cytokines & suppressing inflammatory cytokines with antigen-dependent Treg functionality
ABA-101 is an autologous Treg therapy developed by utilizing patient’s Tregs for expressing TCR to target immunogenic myelin fragments in the CNS, inducing localized anti-inflammatory effect at the disease site

Ref: Abata Therapeutics | Image: Abata Therapeutics

Related Posts:- Atara Biotherapeutics Reports Results for ATA188 in P-II Trial for the Treatment of Non-Active Progressive Multiple Sclerosis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com